Skip to content

Diabetes and weight loss treatments expanded with Eli Lilly's Mounjaro, now offered in a convenient, pen-like device.

Eli Lilly introduces the Mounjaro KwikPen in India, designed for managing Type 2 diabetes and weight loss, with a focus on tailored treatment options.

Diabetes and weight loss treatments expand with Eli Lilly's introduction of Mounjaro in a...
Diabetes and weight loss treatments expand with Eli Lilly's introduction of Mounjaro in a convenient, pen-like delivery system

Diabetes and weight loss treatments expanded with Eli Lilly's Mounjaro, now offered in a convenient, pen-like device.

New Weight Loss Drug Mounjaro Hits Indian Market, Prices Compared to Wegovy

Eli Lilly and Company (India) has launched Mounjaro (tirzepatide), a new weight loss and diabetes treatment, in a KwikPen device across the country. This expansion in the weight loss and diabetes segment comes with a price tag that is comparable to Novo Nordisk's Wegovy.

Mounjaro is available in six different strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg. The prices for these strengths are as follows:

  • Mounjaro's 2.5 mg KwikPen is priced at ₹14,000 per month.
  • Mounjaro's 5 mg KwikPen is priced at ₹17,500 per month.
  • Mounjaro's 7.5 mg KwikPen is not currently available in India.
  • Mounjaro's 10 mg KwikPen is priced at ₹22,000 per month.
  • Mounjaro's 12.5 mg KwikPen is priced at ₹27,500 per month.
  • Mounjaro's 15 mg KwikPen is priced at ₹27,500 per month.

Mounjaro KwikPen contains four fixed doses and is administered once weekly.

On the other hand, Wegovy's prices for three strengths are ₹17,345 per month (0.25 mg; 0.5 mg and 1 mg) or ₹4,336 per dose. Wegovy is available in a four-dose pen-like device in five different strengths. At higher strengths, Wegovy is priced at ₹24,280 (1.7 mg) and ₹26,015 (2.4 mg).

Dr. Rajiv Kovil, a senior diabetologist with Zandra Healthcare, stated that Mounjaro's pen format may take away from its vial versions, similar to how Wegovy's injectable version could divert patients from oral semaglutide. However, he also mentioned that for those who do not like injectables, the respective vial or oral versions of Mounjaro and Wegovy will provide a choice.

It's worth noting that only a small percentage of patients will need higher strengths of either Mounjaro or Wegovy, according to Dr. Kovil. He also expects generic competition from Indian drugmakers for semaglutide next year, potentially leading to lower prices.

When it comes to the 1 mg dose, Mounjaro is not offered or widely recognized at 1 mg dose increments, only at higher doses starting 2.5 mg and above. Wegovy does not have a standalone 1 mg dose marketed; it uses graduated dosing starting 0.25 mg escalating up to 2.4 mg weekly. Thus, a direct price comparison for a 1 mg dose between Mounjaro and Wegovy in India cannot be provided.

To summarize, the cost figures available point to the fact that Mounjaro is generally somewhat cheaper per month than Wegovy but only at the standard available dosing strengths, not at 1 mg. Here's a comparison table for the common dose options in India:

| Drug | Common Dose Options in India (mg) | Approximate Cost Range (₹) per Unit or Month | |----------|-----------------------------------|----------------------------------------------------------------| | Mounjaro | 2.5, 5, 7.5, 10, 15 mg | ₹3,580 (5 mg vial) to ₹7,000+ per vial; ₹14,000–₹17,500/month | | Wegovy | 0.25 to 2.4 mg | ₹17,345 – ₹26,015 per month |

[1] India Pharmaceutical Market [2] Wegovy Prices in India [3] Mounjaro Prices in India [4] Diabetes Care in India

Read also:

Latest